TY - JOUR
T1 - γδ T cells in merkel cell carcinomas have a proinflammatory profile prognostic of patient survival
AU - Gherardin, Nicholas A.
AU - Waldeck, Kelly
AU - Caneborg, Alex
AU - Martelotto, Luciano G.
AU - Balachander, Shiva
AU - Zethoven, Magnus
AU - Petrone, Pasquale M.
AU - Pattison, Andrew
AU - Wilmott, James S.
AU - Quiñones-Parra, Sergio M.
AU - Rossello, Fernando
AU - Posner, Atara
AU - Wong, Annie
AU - Weppler, Alison M.
AU - Shannon, Kerwin F.
AU - Hong, Angela
AU - Ferguson, Peter M.
AU - Jakrot, Valerie
AU - Raleigh, Jeanette
AU - Hatzimihalis, Athena
AU - Neeson, Paul J.
AU - Deleso, Paolo
AU - Johnston, Meredith
AU - Chua, Margaret
AU - Becker, Juergen C.
AU - Sandhu, Shahneen
AU - McArthur, Grant A.
AU - Gill, Anthony J.
AU - Scolyer, Richard A.
AU - Hicks, Rodney J.
AU - Godfrey, Dale I.
AU - Tothill, Richard W.
N1 - Funding Information:
The authors are grateful to following people: Dr. Paul Savage (Brigham Young University, Provo, UT, USA) for providing a-galactosylceramide analogue PBS44 used for production of CD1d-a-GalCer tetramers; Prof. David Fairlie (University of Queensland, Brisbane, Queensland, Australia) for providing 5-ARU used for production of MR1-5-OP-RU tetramers; staff from the flow cytometry facilities at the Department of Microbiology and Immunology at the Peter Doherty Institute and the Melbourne Brain Centre, both at the University of Melbourne, as well as the Peter MacCallum Cancer Centre; University of Melbourne Centre for Cancer Research and Peter MacCallum Cancer Centre Genomics Core Facilities and the Genomics Platform Group at University of Melbourne for their support in generating primary data; Stephen Fox at the Peter MacCallum Cancer Centre for patient samples; Paul Nghiem, Kelly Paulson, and Kristina Lachance at the Fred Hutchinson Cancer Research Center for providing clinical annotation for their published MCC micro-array data. This work was supported by the National Health and Medical Research
Funding Information:
N.A. Gherardin reports grants from Australian Research Council and National Health and Medical Research Council during the conduct of the study. A. Caneborg reports grants from Medical Research Future Fund during the conduct of the study. K.F. Shannon reports personal fees from Merck Serono outside the submitted work. A. Hong reports personal fees from Bayer outside the submitted work. P.J. Neeson reports grants from Bristol-Myers Squibb, Roche/Genentech, Compugen, Allergan, and Merck Sharp & Dohme outside the submitted work. J.C. Becker reports personal fees from Merck Serono, Pfizer, and Sanofi, and grants from 4SC and IQVIA outside the submitted work. S. Sandhu reports grants from AstraZeneca, Merck Sharp & Dohme, Merck Serono, Genentech, Amgen, and Novartis and personal fees from Merck Sharp & Dohme, Bristol-Myers Squibb, and AstraZeneca outside the submitted work. G.A. McArthur reports other support from Genentech/Roche and Array BioPharma during the conduct of the study, as well as other support from Genentech/Roche and Array BioPharma outside the submitted work. R.A. Scolyer reports grants from National Health and Medical Research Council during the conduct of the study, as well as personal fees from Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, Amgen, Bristol-Myers Squibb, Myriad Genetics, and GlaxoSmithKline outside the submitted work. R.J. Hicks reports other support from Telix Pharamceuticals outside the submitted work. D.I. Godfrey reports grants from National Health and Medical Research Council and Australian Research Council during the conduct of the study, as well as other support from CSL, grants from Cancer Council Victoria, personal fees from Avalia Immunotherapies, and a patent for “Compositions and uses thereof” pending outside the submitted work. R.W. Tothill reports grants from National Health and MedicalResearch Council,VictorianCancer Agency,andMedicalResearchFutureFund during the conduct of the study. No disclosures were reported by the other authors.
Publisher Copyright:
©2021 American Association for Cancer Research.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/6/1
Y1 - 2021/6/1
N2 - Merkel cell carcinomas (MCC) are immunogenic skin cancers associated with viral infection or UV mutagenesis. To study T-cell infiltrates in MCC, we analyzed 58 MCC lesions from 39 patients using multiplex-IHC/immunofluorescence (m-IHC/IF). CD4þ or CD8þ T cells comprised the majority of infiltrating T lymphocytes in most tumors. However, almost half of the tumors harbored prominent CD4/CD8 double-negative (DN) T-cell infiltrates (>20% DN T cells), and in 12% of cases, DN T cells represented the majority of T cells. Flow cytometric analysis of single-cell suspensions from fresh tumors identified DN T cells as predominantly Vd2- gd T cells. In the context of gd T–cell inflammation, these cells expressed PD-1 and LAG3, which is consistent with a suppressed or exhausted phenotype, and CD103, which indicates tissue residency. Furthermore, single-cell RNA sequencing (scRNA-seq) identified a transcriptional profile of gd T cells suggestive of proinflammatory potential. T-cell receptor (TCR) analysis confirmed clonal expansion of Vd1 and Vd3 clonotypes, and functional studies using cloned gd TCRs demonstrated restriction of these for CD1c and MR1 antigen-presenting molecules. On the basis of a 13-gene gd T–cell signature derived from scRNA-seq analysis, gene-set enrichment on bulk RNA-seq data showed a positive correlation between enrichment scores and DN T-cell infiltrates. An improved disease-specific survival was evident for patients with high enrichment scores, and complete responses to anti–PD-1/PD-L1 treatment were observed in three of four cases with high enrichment scores. Thus, gd T–cell infiltration may serve as a prognostic biomarker and should be explored for therapeutic interventions.
AB - Merkel cell carcinomas (MCC) are immunogenic skin cancers associated with viral infection or UV mutagenesis. To study T-cell infiltrates in MCC, we analyzed 58 MCC lesions from 39 patients using multiplex-IHC/immunofluorescence (m-IHC/IF). CD4þ or CD8þ T cells comprised the majority of infiltrating T lymphocytes in most tumors. However, almost half of the tumors harbored prominent CD4/CD8 double-negative (DN) T-cell infiltrates (>20% DN T cells), and in 12% of cases, DN T cells represented the majority of T cells. Flow cytometric analysis of single-cell suspensions from fresh tumors identified DN T cells as predominantly Vd2- gd T cells. In the context of gd T–cell inflammation, these cells expressed PD-1 and LAG3, which is consistent with a suppressed or exhausted phenotype, and CD103, which indicates tissue residency. Furthermore, single-cell RNA sequencing (scRNA-seq) identified a transcriptional profile of gd T cells suggestive of proinflammatory potential. T-cell receptor (TCR) analysis confirmed clonal expansion of Vd1 and Vd3 clonotypes, and functional studies using cloned gd TCRs demonstrated restriction of these for CD1c and MR1 antigen-presenting molecules. On the basis of a 13-gene gd T–cell signature derived from scRNA-seq analysis, gene-set enrichment on bulk RNA-seq data showed a positive correlation between enrichment scores and DN T-cell infiltrates. An improved disease-specific survival was evident for patients with high enrichment scores, and complete responses to anti–PD-1/PD-L1 treatment were observed in three of four cases with high enrichment scores. Thus, gd T–cell infiltration may serve as a prognostic biomarker and should be explored for therapeutic interventions.
UR - http://www.scopus.com/inward/record.url?scp=85107602534&partnerID=8YFLogxK
U2 - 10.1158/2326-6066.CIR-20-0817
DO - 10.1158/2326-6066.CIR-20-0817
M3 - Article
C2 - 33674358
AN - SCOPUS:85107602534
SN - 2326-6066
VL - 9
SP - 612
EP - 623
JO - Cancer Immunology Research
JF - Cancer Immunology Research
IS - 6
ER -